Emerg Infect Dis by Foissac, Maud et al.
In a recent immunohistochemistry study (7), antibod-
ies against Em2G11 have shown excellent properties for 
distinguishing between cystic and alveolar echinococ-
cosis. Although reported to not cross-react with purified 
laminated layer fractions from in vitro–kept E. vogeli (10), 
antibodies against Em2G11 exhibited an unusual and pos-
sibly discriminatory staining pattern when applied to the 
E. vogeli lesion from the patient reported here. Antibodies 
against EM10, which has not before been used for species 
discrimination on tissue sections, have also shown different 
staining properties.
Our findings suggest that there may be more undiag-
nosed cases of polycystic neotropical echinococcoses in 
immigrants from South America. In retrospect, the treat-
ment (although aimed at E. granulosus) was successful 
despite the polycystic and proliferative nature of E. vogeli 
lesions, as indicated by an uneventful prolonged follow-up 
period for this patient with a well-circumscribed liver le-
sion. If neotropical echinococcosis had been considered be-
fore surgery (on the basis of radiologic features and the pa-
tient’s origin), the management would also have included a 
preoperative and prolonged course of albendazole therapy.
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To the Editor: In October 2013, autochthonous 
transmission of chikungunya was detected in the Carib-
bean area, which resulted in the current epidemic of chi-
kungunya in the Western Hemisphere (1). The chikun-
gunya virus strain that caused this epidemic belongs to 
the Asian lineage, not to the strain descending from the 
East/Central/South African (ECSA) lineage that spread 
in the Indian Ocean region after 2004. This ECSA lin-
eage was reported mainly to cause long-lasting muscu-
loskeletal and rheumatic disorders in chikungunya vi-
rus–infected patients (2–8). In 1984 in South Africa, 
Brighton and Simson reported post-chikungunya destruc-
tive polyarthritis (6). Twenty years later, the arthritogenic 
pathogenesis of viruses in the ECSA chikungunya virus 
lineage was confirmed after outbreaks in the Indian Ocean 
region (2–5,7,8).
Because >870,000 suspected cases of chikungu-
nya have occurred during the past 12 months in the 
Western Hemisphere (http://www.paho.org/hq/index.
php?option=com_content&view=article&id=9436), it is 
crucial to know whether infection with the epidemic Asian 
strain will cause chronic inflammatory and potentially de-
structive rheumatism. We report post-chikungunya rheu-
matoid arthritis from Saint Martin, the epicenter of the cur-
rent epidemic.
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A 70-year-old woman (artist–painter) in Saint Martin 
sought treatment in June 2014 for joint pains and disabili-
ties persisting after chikungunya. Her medical history in-
cluded high blood pressure, hypothyroidism, and 3 dengue 
infections. During October 2013, the patient had high-grade 
fever, intense fatigue, and a maculopapular troncular exan-
thema without lymphadenopathy. Five days later, she had 
distal polyarthritis (joint pain and swelling) in interphalan-
geal joints, wrists, and ankles without plantar involvement. 
Recent infection with chikungunya virus was confirmed 
(IgM and IgG against chikungunya virus was detected in 2 
blood samples), and recent dengue was excluded according 
to the criteria of the National Reference Center on Arbo-
viral Diseases (http://www.niaid.nih.gov/labsandresources/
resources/dmid/wrceva/Pages/default.aspx).
Despite initial brief improvement, the patient never 
totally recovered and subsequently chronic polyarthritis 
developed, which involved >10 joints, including interpha-
langeal joints, wrists, and knees. Nonsteroidal antiinflam-
matory drugs did not relieve the diffuse pain, stiffness, 
and swelling. She was given oral corticotherapy (20 mg/
day) beginning in January 2014. She was referred to an-
other hospital in France 5 months later because of treatment 
failure. She reported continuous pain in the left knee and 
wrists and multiple tenosynovitis on flexors and extensors 
of the fingers (Figure). She did not report any fever or axial, 
shoulder, or hip pain. Radiographs of the involved joints 
showed no abnormalities.
The patient had mild inflammation (C-reactive pro-
tein level 13 mg/L, fibrinogen level 3.4 g/L) but no spe-
cific autoimmunity (results were negative for anticitrulli-
nated peptide antibodies, rheumatoid factor, antineutrophil 
cytoplasmic antibodies, and antinuclear antibodies). Se-
rologic results for viruses other than chikungunya virus 
were negative or indicated past vaccination. The patient’s 
condition met the 2010 American College of Rheumatolo-
gy/European League against Rheumatism criteria for rheu-
matoid arthritis (https://www.rheumatology.org/practice/
clinical/classification/ra/ra_2010.asp), and the only cause 
observed for this disease was acute chikungunya. For this 
corticosteroid-resistant, seronegative, and nondestructive 
post-chikungunya rheumatoid arthritis, methotrexate was 
prescribed at a weekly low dose after exclusion of contra-
indications, but the patient was not followed-up after she 
returned to Saint Martin.
The reported case was caused by chikungunya virus 
infection during an epidemic in Saint Martin in October 
2013. This unfavorable post-chikungunya outcome of 
chronic inflammatory rheumatism 8 months later indi-
cates a probable course of post-chikungunya disorders in 
the Western Hemisphere, as has already been observed in 
Africa and Asia. Previous outbreaks in Réunion and India 
offer insights regarding patients’ post-chikungunya chronic 
status with long-lasting pain and disability, impaired qual-
ity of life, and extensive treatment (2,3,9).
The spectrum of post-chikungunya rheumatic and 
musculoskeletal disorders includes multiple tendinitis and 
tenosynovitis, plantar fasciitis, mechanical disbalance in 
susceptible joints, tunnel syndromes, edematous polyar-
thralgia, rheumatoid arthritis, and psoriatic arthritis (2,4,5). 
Although the proportion of patients with chronic disease 
has decreased, post-chikungunya chronic inflammatory 
rheumatism, mostly rheumatoid arthritis, develops in ≈5% 
of these patients (8). These patients had a poor prognosis 
and were given disease-modifying anti-rheumatic drugs 
(DMARDs), despite the postinfectious origin of rheuma-
tism (4,5). Patients with post-chikungunya rheumatoid ar-
thritis should benefit from methotrexate, which is recom-
mended for treatment of classic rheumatoid arthritis (10).
In our experience, resistance to or dependence on 
corticosteroids beyond the third month after disease onset 
is highly evocative of post-chikungunya chronic inflam-
matory rheumatism. This finding requires early treatment 
with DMARDs to control the inflammatory process, pre-
vent bone erosions, and prevent inevitable side effects of 
prolonged corticotherapy. To date, the efficacy of differ-
ent DMARDs for treatment of post-chikungunya chronic 
inflammatory rheumatism has not been evaluated. There-
fore, physicians should follow the international guidelines 
for treatment of classic rheumatoid arthritis and psoriatic 
polyarthritis, which recommend methotrexate as first-line 
treatment for patients fulfilling chronic inflammatory rheu-
matism criteria after 3 months of evolution.
We found that the Asian strain of chikungunya virus 
has induced arthritic disorders in the Western Hemisphere. 
Thus, a possible increase in post-chikungunya rheumatoid 
arthritis should not be overlooked. Physicians and public 
health authorities should prepare a response to the patients’ 
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Figure. Swollen and stiff hands of a 70-year-old woman with post-
chikungunya rheumatoid arthritis 10 months after acute infection 
with chikungunya virus, Saint Martin.
post-chikungunya stage in the epidemic areas. Clinical vig-
ilance is recommended to identify patients with unfavor-
able outcomes 3 months after disease onset and for those 
in whom post-chikungunya chronic inflammatory rheuma-
tism develops and who require specific treatment. Detailed 
guidelines for diagnosis and treatment of these patients 
with chronic rheumatoid arthritis are needed.
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To the Editor: Human monocytic ehrlichiosis (HME), 
a tickborne zoonosis caused by the rickettsial pathogen 
Ehrlichia chaffeensis (Rickettsiales: Anaplasmataceae), 
is considered an emerging pathogen in the United States 
and, increasingly, in many countries around the world (1). 
In Costa Rica, past reports of human cases of ehrlichiosis 
were diagnosed solely by clinical evaluation and cytomor-
phology (2,3); recent studies have detected E. canis in dogs 
and their ectoparasites (4,5). However, molecular detection 
of natural Ehrlichia infection detected in humans in Costa 
Rica has not been reported.
In a small rural area of Zarcero, province of Alajuela, 
north central region of Costa Rica, blood samples were 
drawn from 20 patients who had histories of tick bites and 
nonspecific symptoms of fatigue, arthralgia, and myalgia 
beginning >1 year before sampling. The samples were re-
ferred for Ehrlichia molecular analysis. In addition, blood 
samples were drawn from 2 patients of 2 health care clinics 
in the Alajuela province districts of San Carlos and Ala-
juela who had clinical signs compatible with recent eh-
rlichiosis; the samples were sent for confirmation by PCR. 
All anticoagulated samples were transported within 4 hours 
to the laboratory for processing. No serologic assays were 
performed; cytomorphologic estimation and laboratory 
data were provided from the local health facilities, mostly 
generated 1 year before this molecular analysis. 
DNA was isolated the same day of sampling from 
whole blood (200 μL) by using the QIAamp Blood Kit 
(QIAGEN, Santa Clarita, CA, USA) according to the man-
ufacturer’s instructions. Purified DNA from each blood 
sample was quantified by spectrophotometry, yielding 20–
32 ng/μL of DNA. Nested PCR assays were performed as 
described (6,7). To avoid DNA contamination, first PCR, 
second PCR, and electrophoresis were performed in sepa-
rate rooms, following strict rules of pipetting and clean-
ing, and repeated >3 times. In addition, endpoint PCR for 
the variable-length PCR target gene was performed on 
samples that were positive in the nested assay, according 
to Paddock et al. (8). For DNA sequencing, PCR reactions 
were performed, and products were separated by agarose 
gel electrophoresis. A nested PCR mixture containing wa-
ter and 1 containing unrelated Brucella abortus DNA were 
used as negative controls in every assay. As an internal 
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